Molecular pathology of lung cancer: key to personalized medicine. - Wikidata - awgldk - TriplyDB

Molecular pathology of lung cancer: key to personalized medicine.

Molecular pathology of lung cancer: key to personalized medicine.

http://www.wikidata.org/entity/Q27691299

about

Multiwalled carbon nanotube-induced gene signatures in the mouse lung: potential predictive value for human lung cancer risk and prognosis Liquid biopsy in early stage lung cancer Tumour biomarkers: homeostasis as a novel prognostic indicator Molecular features in arsenic-induced lung tumors P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform Discovering and understanding oncogenic gene fusions through data intensive computational approaches Fluorescence in situ hybridization in surgical pathology: principles and applications.Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer Distinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung.Alveolar type II cells possess the capability of initiating lung tumor development Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report.Novel workflow for combining Raman spectroscopy and MALDI-MSI for tissue based studies.Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.Personalized targeted therapy for lung cancer Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions.Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait.Drug Resistance to EGFR Inhibitors in Lung Cancer Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck.KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.Low-frequency KRAS mutations are prevalent in lung adenocarcinomas Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.Next-generation sequencing for lung cancer.Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.Decrease of FSTL1-BMP4-Smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma.Pingyangmycin and Bleomycin Share the Same Cytotoxicity Pathway.

P2860

Q23918758-96B28AF3-4337-4A79-83A1-B02FE9E32194 Q28065994-D3826A8F-4CCD-4FF3-A5E7-B7DAF0F4E17A Q28069898-DFCA7ADB-F26D-4FFD-A7A5-A73165841F3A Q28396910-19DCF3CD-0691-4D01-84AE-1749D6C777DE Q28540825-75C9D63E-9EAB-4902-8D5E-F120CEF3C1E5 Q30386192-605E767C-A342-4CD2-9A9E-C6796C3AC487 Q31083417-5DF48782-C01E-40E2-9633-E9A97CB3CE9D Q33593910-E83B2E7E-D042-48E3-BF64-7B57AB9FF8F8 Q33769117-94D76009-6092-42BF-A887-2D311C0F9F97 Q34029261-EE0234E6-886C-4FF4-B2DF-66F5C0FEFD6C Q34295621-5C50F99F-E40B-44FD-9C96-773BAFAC988F Q34427314-E11527C4-85B5-47F9-AA15-0D5708FFE538 Q34535276-B96EBC7B-FF45-491E-9F90-BF0113AB1C80 Q35043965-E0BD2E34-4636-42A0-AF45-573F65478908 Q35256540-37FED02A-7E67-4954-AD5B-600FC1124952 Q35549714-2E9CFEB2-39A5-4D97-B654-932336F9CF3E Q35759003-B798C0E3-DB05-44C1-9B09-3A2B29DAD5E0 Q35776848-FDCAA8C8-3C65-47DB-8B15-366CAE9228AB Q35843530-979A86C0-B027-4CC2-BD01-3130EADCE4EC Q36040606-9930B959-EBDA-488B-850A-CD27CF0C1B4D Q36063032-6CE01C29-36F1-45D5-8886-DFB6A30DC7D0 Q36321826-D8965B17-B8A9-4504-BFB7-7CD9EA68A40E Q36331604-182DE768-D76A-4018-A0A3-A1AF42EF1F72 Q36439363-1172E88A-F6BD-4747-98D7-1C53E4D98C89 Q36662504-3AF74BEC-6723-4DB9-92B3-BE15C29B91AA Q36834883-AB3CC57A-5B58-4207-9289-9EE5EC9378DA Q37059865-A896259C-6E43-41B3-BF25-22D7A34E187E Q37067360-3CB17923-1CC8-4BE3-BAE3-5C5AC100B8AE Q37238413-567EDE23-C8A7-4200-B268-0E8D763FFA77 Q37375834-11DD8BA0-26E0-4174-B692-C9EEEF09A39C Q37638241-D243DF42-E991-4502-A6C2-A2785872CAF4 Q37703407-312452DF-EA0A-4150-B248-72A053263126 Q38081987-5C1564A0-3F8D-4DA8-A3AC-32F48AE55C95 Q38087239-BF69663F-8344-4119-9505-30F0847B337C Q38131798-7CE0F5AC-26A0-4058-91B6-2398B2029EF2 Q38271717-FD96AAC1-8AD0-482B-9DF1-436E27BE3141 Q38398139-3310A39F-BD45-450B-B0B8-0A5753D93CB3 Q38658503-53ACAADD-75ED-4981-99B6-D94EE632A695 Q38693861-07CC17FB-6AA6-4B1F-9C2A-7A67BE6E14B5 Q38759996-F7E3C959-0745-43D5-BE80-F4346C6615A6

P2860

Molecular pathology of lung cancer: key to personalized medicine.

http://www.wikidata.org/entity/Q27691299

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Molecular pathology of lung cancer: key to personalized medicine.

@ast

Molecular pathology of lung cancer: key to personalized medicine.

@en

Molecular pathology of lung cancer: key to personalized medicine.

@nl

type

label

Molecular pathology of lung cancer: key to personalized medicine.

@ast

Molecular pathology of lung cancer: key to personalized medicine.

@en

Molecular pathology of lung cancer: key to personalized medicine.

@nl

prefLabel

Molecular pathology of lung cancer: key to personalized medicine.

@ast

Molecular pathology of lung cancer: key to personalized medicine.

@en

Molecular pathology of lung cancer: key to personalized medicine.

@nl

P1433

Q27691299-887F66EA-11DA-46AC-8A2D-24AC66115E0E

P1476

Q27691299-088EDE84-F481-4C1D-BADB-A51C14B9E5D7

P2093

Q27691299-1286A81A-0420-4A1B-814B-BDCDD415449A

Q27691299-356C39C5-B6E2-4324-A429-4B39676BACD2

Q27691299-66B3F7CA-5878-4276-9F9E-A3211E15B7AD

Q27691299-6C7B7EFC-59F6-4E67-9A89-2F650A648E20

Q27691299-883E7EE6-F4E4-4E57-BD87-B76AA3B6F788

Q27691299-92224087-4F85-45E9-8778-914A75179D2C

Q27691299-B22AE6A5-FDED-4E25-9FE8-48FAE23F1237

Q27691299-CA8B18CD-9016-4ED0-98A3-FFFF73F21DCB

Q27691299-CEE751D6-B4C2-4F5F-9005-63BE5102CEFF

P2860

Q27691299-00AF4EF4-5263-4E29-822A-87C82C5154C5

Q27691299-00DAC53F-9BCE-4818-9422-7008F7B8CC0D

Q27691299-00DC52F0-9ABD-4C45-B734-60A6FD2D8C53

Q27691299-014D9C34-EBCB-4F7A-AC36-514876305F33

Q27691299-02A92028-5A49-4529-971A-7F44D1E9D685

Q27691299-02D3F651-6D7A-473B-A332-5C58ACD6A1F4

Q27691299-02F3E2F8-88FB-401B-BFEB-E097320AAC12

Q27691299-05B69BFB-184B-4245-B273-8733A4AFB27A

Q27691299-06B863C4-3FF1-4D99-9921-6468F43FFF37

Q27691299-07D04F88-21CF-4555-83A5-3160E1AD1BFB

P2888

Q27691299-17BCE5C6-9807-40FA-8D83-665625C6001E

P304

Q27691299-555A8089-5CD4-41D9-BAF9-4B001253B43F

P31

Q27691299-4B047C1B-845F-413F-A0B0-7F875DEF2D6D

P3181

Q27691299-69189212-6B4D-4F91-9108-C154A2C7E60D

P356

Q27691299-F89590CF-08B3-480D-AE92-CDCD4B87C3C3

P433

Q27691299-C3477AAF-BB24-484F-89F9-4B1CF9BA72C4

P478

Q27691299-ACF69861-6D9C-44F6-8C09-0EEE8CDDC0A5

P577

Q27691299-ADA81022-B18D-4335-AAD7-F19D6789DCFD

P5875

Q27691299-6483520C-12E4-4C6A-9E9B-61D8BEC88840

P6179

Q27691299-4DCD1A3A-7368-4118-8353-46000C6B7F19

P698

Q27691299-14E76E91-E09B-4F34-BB86-19CACAA7C1EE

P921

Q27691299-2b7d680c-43b0-4629-9d3e-faf9d4938397

P3181

P356

MODPATHOL.2011.215

P1433

Modern Pathology

P1476

Molecular pathology of lung cancer: key to personalized medicine.

@en

P2093

Alexander RE

http://www.w3.org/2001/XMLSchema#string

Cheng L

http://www.w3.org/2001/XMLSchema#string

Cramer HM

http://www.w3.org/2001/XMLSchema#string

Cummings OW

http://www.w3.org/2001/XMLSchema#string

Davidson DD

http://www.w3.org/2001/XMLSchema#string

Lopez-Beltran A

http://www.w3.org/2001/XMLSchema#string

Maclennan GT

http://www.w3.org/2001/XMLSchema#string

Montironi R

http://www.w3.org/2001/XMLSchema#string

Zhang S

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Global cancer statistics

Anaplastic lymphoma kinase: signalling in development and disease

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

The biology and treatment of EML4-ALK non-small cell lung cancer

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

Somatic mutations affect key pathways in lung adenocarcinoma

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

P2888

modpathol.2011.215

P304

347-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2166093

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/MODPATHOL.2011.215

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221782054

http://www.w3.org/2001/XMLSchema#string

P6179

1016408971

http://www.w3.org/2001/XMLSchema#string

P698

22282308

http://www.w3.org/2001/XMLSchema#string

P921